Clinical Features of COVID-19 on patients with neuromyelitis optica spectrum disorders

dc.contributor.authorDourado Junior, Mário Emílio Teixeira
dc.contributor.authorFerreira, Lis Campos
dc.contributor.authorPereira, Samira Luisa Apostolos
dc.contributor.authoret, al
dc.contributor.authorIDhttps://orcid.org/0000-0002-9462-2294pt_BR
dc.date.accessioned2023-07-26T19:18:47Z
dc.date.available2023-07-26T19:18:47Z
dc.date.issued2021
dc.description.resumoBackground and Objectives To describe the clinical features and disease outcomes of coronavirus disease 2019 (COVID-19) in patients with neuromyelitis optica spectrum disorder (NMOSD). Methods The Neuroimmunology Brazilian Study Group has set up the report of severe acute respiratory syndrome (SARS-CoV2) cases in patients with NMOSD (pwNMOSD) using a designed web-based case report form. All neuroimmunology outpatient centers and individual neurologists were invited to register their patients across the country. Data collected between March 19 and July 25, 2020, were uploaded at the REDONE.br platform. Inclusion criteria were as follows: (1) NMOSD diagnosis according to the 2015 International Panel Criteria and (2) confirmed SARS-CoV2 infection (reverse transcription-polymerase chain reaction or serology) or clinical suspicion of COVID-19, diagnosed according to Center for Disease Control / Council of State and Territorial Epidemiologists (CDC/CSTE) case definition. Demographic and NMOSD-related clinical data, comorbidities, disease-modifying therapy (DMT), COVID-19 clinical features, and severity were described. Results Among the 2,061 pwNMOSD followed up by Brazilian neurologists involved on the registry of COVID-19 in pwNMOSD at the REDONE.br platform, 34 patients (29 women) aged 37 years (range 8–77), with disease onset at 31 years (range 4–69) and disease duration of 6 years (range 0.2–20.5), developed COVID-19 (18 confirmed and 16 probable cases). Most patients exhibited mild disease, being treated at home (77%); 4 patients required admission at intensive care units (severe cases); and 1 patient died. Five of 34 (15%) presented neurologic manifestations (relapse or pseudoexacerbation) during or after SARS-CoV2 infection. Discussion Most NMOSD patients with COVID-19 presented mild disease forms. However, pwNMOSD had much higher odds of hospitalization and intensive care unit admission comparing with the general Brazilian population. The frequency of death was not clearly different. NMOSD disability, DMT type, and comorbidities were not associated with COVID-19 outcome. SARS-CoV2 infection was demonstrated as a risk factor for NMOSD relapses. Collaborative studies using shared NMOSD data are needed to suitably define factors related to COVID-19 severity and neurologic manifestations.pt_BR
dc.identifier.citationDOURADO JUNIOR, Mário Emílio Teixeira, et al. Clinical Features of COVID-19 on Patients With Neuromyelitis Optica Spectrum Disorders. Neurology - Neuroimmunology Neuroinflammation, [S.L.], v. 8, n. 6, p. 1060, 26 ago. 2021. Ovid Technologies (Wolters Kluwer Health). http://dx.doi.org/10.1212/nxi.0000000000001060. Disponível em: https://nn.neurology.org/content/8/6/e1060. Acesso em: 14 jul. 2023.pt_BR
dc.identifier.doihttp://dx.doi.org/10.1212/nxi.0000000000001060
dc.identifier.urihttps://repositorio.ufrn.br/handle/123456789/54207
dc.languageenpt_BR
dc.publisherNeuroimmunology Neuroinflammationpt_BR
dc.subjectneuromyelitis opticapt_BR
dc.subjectdistúrbios do espectropt_BR
dc.subjectneuromielite ópticapt_BR
dc.titleClinical Features of COVID-19 on patients with neuromyelitis optica spectrum disorderspt_BR
dc.typearticlept_BR

Arquivos

Pacote Original

Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
ClinicalFeaturesPatients_DouradoJr_2021.pdf
Tamanho:
266.11 KB
Formato:
Adobe Portable Document Format
Nenhuma Miniatura disponível
Baixar

Licença do Pacote

Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.45 KB
Formato:
Item-specific license agreed upon to submission
Nenhuma Miniatura disponível
Baixar